StockData

Kamada vs Organogenesis

KMDA and ORGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KMDA and ORGO compare

Kamada grew revenue faster over the last twelve months (13.2% versus 6.5% for Organogenesis).

Organogenesis scores higher on the StockData Score (9 against 5 for Kamada), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKMDAORGO
Size and price
Market cap–$103M
Share price$8.11$0.803
Change, 1 year14.5%−87.1%
Change, 5 years28.5%−91.9%
Beta (5Y)0.840.59
Employees393854
StockData Score
Total score59 (better)
Valuation score01 (better)
Growth score2 (better)0
Performance score03 (better)
Health score35 (better)
Dividend score00
Valuation
P/S–0.2×
P/B–0.7×
P/FCF–5.0×
FCF yield–20.2%
Growth
Revenue growth (TTM)13.2% (better)6.5%
Revenue growth, 5Y average6.3%10.8% (better)
EPS growth, 5Y average−1.6%0.00% (better)
Profitability
Gross margin40.8%–
Operating margin14.5% (better)−7.8%
Net margin–−18.4%
FCF margin–4.6%
Return on equity–−44.1%
Return on invested capital–−21.7%
Financial health
Debt / equity–0.00
Net debt / EBITDA−0.54–
Interest coverage26.8×–
Current ratio4.06 (better)3.52
Altman Z-score–1.26
Piotroski F-score–5
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions8.6%53.2%
Held by insiders45.3%–
Insider net buying, 12 months−$1.7M−$988K (better)
Short interest, % of float0.53%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.